PIK3CA and cervical cancer: In summary, our studies suggest that targeting the PI3K pathway may represent a novel and promising strategy that may provide therapeutic benefit in cervical cancer patients whose tumours express PIK3CA-E545K, by restoring cisplatin sensitivity and possibly reducing a more migratory potential.